Title: Study of Effect of Metformin in PCOS Patients
Authors: Dr Anuranjita Pallavi, Dr Pallavi Vishwekar
DOI: https://dx.doi.org/10.18535/jmscr/v4i12.103
Abstract
INTRODUCTION
Polycystic ovary syndrome (PCOS), also called hyperandrogenic anovulation (HA), or Stein-Leventhal syndrome, is one of the most common endocrinal disorders among females. PCOS produces symptoms in approximately 5% to 10% of women of reproductive age (approximately 12 to 45 years old)1. It is characterized by chronic anovulation with either oligomenorrhoea or amenorrhoea and hyperandrogenism and is the most common cause of anovulatory infertility and hirsutism (Solomon, 1999).2 Anovulation results in irregular menstruation, amenorrhoea, and ovulation-related infertility. Hormone imbalance generally causes acne and hirsutism. Insulin resistance is associated with obesity, type 2 diabetes, and high cholesterol levels. The symptoms and severity of the syndrome vary greatly among affected women.
References
1. Asuncion M, Calvo RM, SanMillan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434-38.
2. Solomon CG The epidemiology of polycystic ovarian syndrome: Prevalence and associated disease risks. Endocrinol Metab Clin North Am1999;28:247-63
3. Genazzani AD, Baltaglia C, Malavasi B, Slrucchi C, Torlolani F, Gamba O, Metformin ad minis t ration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in non obese patients with polycystic ovary syndrome. Fertil Steril 2004; 81(1).T14-119.
4. Nestler JE and Jakubowicz DJ. Decreases in ovarian cytochrome p450 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New Eng1 J Med 1996;335:617-623.
5. Uliger R. Insulin and the polycystic ovary syndrome. N Eng1 J Med 1996;335:657-658.
6. Seli E, Duelba AJ. Optimizing ovulation induction in women with polycystic ovary syndrome. CurrOpinObstetGynecol 2002; 14:245-254.
7. Futterweit W. Polycystic ovary syndrome: Clinical perspectives and management. ObstetGynecolSurv 1999; 54:403-413.
8. Velazquez EM, Acosta A, Mendoza S. Menstrual cyclity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90:392-395.
9. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin, therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. FertilSteril 2000; 73:1149-1154.
10. Vandermolen T, Kalis VS, Evans WS, Slovall 1.)W, Kauma SW aiulNestler ]E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. FertilSleril 2001;75:310-315.
11. Acbay O, GundogduS. Can metformin reduce insulin resistance in polycystic ovary syndrome? FertilSteril 1996; 65:946-949.
12. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J ClinEndocrinolMetab 1997; 82:524-530.
13. Harborne L, Fleming R, Lyall H, Sattar N and Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J ClinEndocrinol and Metab 2003; 88:4116-4123.
14. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: Clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol 2002; 16:275-284.
15. Conway et al. Skin manifestations of polycystic ovary syndrome. In: Kovacs GT, editor Polycystic ovary syndrome, Cambridge University Press, New York, 2000; pp.79-97.
16. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J ObstetGynecol 1992; 167:1807-1812.
17. Vrbikova et al. The effects of long term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol2001; 144:619-628.
18. Mac-Paimill. Polycystic ovary syndrome: An overview from topics in advanced practice nursing Journal 2(3) 2002 © 2002 Medscape.
19. Pasquali et al. Effect of long term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with or without polycystic ovary syndrome. JClin EndocrinolMetab 2001; 85:2767-2774.
20. Glueck MD. Insulin sensitizing drug a revolution in the treatment of PCOS - PCOS Scientific update 6/02/1999 CJ Jewish Hospital Cholesterol Centre.
21. Hung Yu Ng E, Ming Sun Wat N, Chung Ho P. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene resistant polycystic ovaries, a randomized double blinded placebo controlled trial. Hum Reprod 2001; 16:1625-1631.
22. Bergh C, Carisson B, Olsson JH, Selieskog U, Hiilensjo T. Regulation of androgen production in cultured human thecal cells by IGF-l and insulin. Fertil Steril 1993; 59:323-331.
23. Nestler JE and Jakubowicz DJ. Decreases in ovarian cytochrome p450 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New Engl J Med 1996;335:617-623.
24. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome, a randomized study. J ClinEndocrinolMetab 2000; 85:3161-68.
25. Marea AL, Morgante G, Palumbo M, Cianci A, Petraglia F, Leo VD. Insulin lowering treatment reducesarormatase activity in response to follicle stimulating hormone in women with polycystic ovary syndrome. FertilSteril 2002; 78:1234-1239.
26. Nestler JE, Jakubowicz DJ, Evans WS and Pasquali K. Effects of metformin spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876-1880.
27. Kazerooni T, Dehghan-Kooshkghazi M.Effects of metformin therapy on Oe- hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003 Feb; 17(l):51-6.
28. Chou K H, von Eye CH, CappE, Spritzer PM: Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. HormMetab Res 2003; 35:86-91.
29. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ami Intern Med 2002; 137:25-33.